Opthea (FRA:UKJ) Total Liabilities : €300.32 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Opthea Total Liabilities?

Opthea's Total Liabilities for the quarter that ended in Dec. 2024 was €300.32 Mil.

Opthea's quarterly Total Liabilities increased from Dec. 2023 (€195.70 Mil) to Jun. 2024 (€245.81 Mil) and increased from Jun. 2024 (€245.81 Mil) to Dec. 2024 (€300.32 Mil).

Opthea's annual Total Liabilities increased from Jun. 2022 (€11.42 Mil) to Jun. 2023 (€96.45 Mil) and increased from Jun. 2023 (€96.45 Mil) to Jun. 2024 (€245.81 Mil).

Opthea Total Liabilities Historical Data

The historical data trend for Opthea's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Total Liabilities Chart

Opthea Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Liabilities

Get a 7-Day Free Trial

4.32

2.59

11.42

96.45

245.81

Opthea Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial															92.08	96.45	195.70	245.81	300.32

Opthea Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Opthea's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	59.508	+	(131.505	+	54.792
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0.009	+	0)
	=	245.81

Total Liabilities	=	Total Assets (A: Jun. 2024 )	-	Total Equity (A: Jun. 2024 )
	=	175.387	-	-70.427
	=	245.81

Opthea's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	87.618	+	(150.135	+	62.571
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	300.32

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	139.21	-	-161.113
	=	300.32

Opthea Total Liabilities Related Terms

Thank you for viewing the detailed overview of Opthea's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (FRA:UKJ) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

OPT:USA OPT:Australia

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

Opthea Headlines

No Headlines